相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Parkinson's disease: evolution of cognitive impairment and CSF Aβ1-42 profiles in a prospective longitudinal study
Stefanie Lerche et al.
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY (2019)
Method comparison study of the Elecsys® β-Amyloid (1-42) CSF assay versus comparator assays and LC-MS/MS
Leslie M. Shaw et al.
CLINICAL BIOCHEMISTRY (2019)
Impact of Pre-Analytical Differences on Biomarkers in the ADNI and PPMI Studies: Implications in the Era of Classifying Disease Based on Biomarkers
Tessandra Stewart et al.
JOURNAL OF ALZHEIMERS DISEASE (2019)
Cognitive and Pathological Influences of Tau Pathology in Lewy Body Disorders
David Coughlin et al.
ANNALS OF NEUROLOGY (2019)
Cerebrospinal fluid α-synuclein contributes to the differential diagnosis of Alzheimer's disease
Min Shi et al.
ALZHEIMERS & DEMENTIA (2018)
CSF biomarkers of Alzheimer's disease concord with amyloid-β PET and predict clinical progression: A study of fully automated immunoassays in BioFINDER and ADNI cohorts
Oskar Hansson et al.
ALZHEIMERS & DEMENTIA (2018)
CSF tau and β-amyloid predict cerebral synucleinopathy in autopsied Lewy body disorders
David J. Irwin et al.
NEUROLOGY (2018)
Evolution of cerebrospinal fluid total alpha-synuclein in Parkinson's disease
Marthe Gurine Forland et al.
PARKINSONISM & RELATED DISORDERS (2018)
The Parkinson's progression markers initiative (PPMI) - establishing a PD biomarker cohort
Kenneth Marek et al.
ANNALS OF CLINICAL AND TRANSLATIONAL NEUROLOGY (2018)
Cross-Sectional and Longitudinal Cognitive Correlates of FDDNP PET and CSF Amyloid-β and Tau in Parkinson's Disease
Mariateresa Buongiorno et al.
JOURNAL OF ALZHEIMERS DISEASE (2017)
Clinical variables and biomarkers in prediction of cognitive CrossMark impairment in patients with newly diagnosed Parkinson's disease: a cohort study
Anette Schrag et al.
LANCET NEUROLOGY (2017)
Neuropathological and genetic correlates of survival and dementia onset in synucleinopathies: a retrospective analysis
David Irwin et al.
LANCET NEUROLOGY (2017)
Longitudinal CSF biomarkers in patients with early Parkinson disease and healthy controls
Brit Mollenhauer et al.
NEUROLOGY (2017)
Multiple modality biomarker prediction of cognitive impairment in prospectively followed de novo Parkinson disease
Chelsea Caspell-Garcia et al.
PLOS ONE (2017)
Accuracy of cerebrospinal fluid Aβ1-42 measurements: evaluation of pre-analytical factors using a novel Elecsys immunosassay
Malgorzata Rozga et al.
CLINICAL CHEMISTRY AND LABORATORY MEDICINE (2017)
CSF β-Amyloid 1-42 Predicts Progression to Cognitive Impairment in Newly Diagnosed Parkinson Disease
Mark Terrelonge et al.
JOURNAL OF MOLECULAR NEUROSCIENCE (2016)
CSF biomarkers associated with disease heterogeneity in early Parkinson's disease: the Parkinson's Progression Markers Initiative study
Ju-Hee Kang et al.
ACTA NEUROPATHOLOGICA (2016)
Technical performance of a novel, fully automated electrochemiluminescence immunoassay for the quantitation of β-amyloid (1-42) in human cerebrospinal fluid
Tobias Bittner et al.
ALZHEIMERS & DEMENTIA (2016)
Longitudinal Measurements of Cerebrospinal Fluid Biomarkers in Parkinson's Disease
Sara Hall et al.
MOVEMENT DISORDERS (2016)
A/T/N: An unbiased descriptive classification scheme for Alzheimer disease biomarkers
Clifford R. Jack et al.
NEUROLOGY (2016)
Phenotypic differences based on staging of Alzheimer's neuropathology in autopsy-confirmed dementia with Lewy bodies
Guerry M. Peavy et al.
PARKINSONISM & RELATED DISORDERS (2016)
Cognitive performance and neuropsychiatric symptoms in early, untreated Parkinson's disease
Daniel Weintraub et al.
MOVEMENT DISORDERS (2015)
Neurodegenerative CSF markers in genetic and sporadic PD: Classification and prediction in a longitudinal study
Kathrin Brockmann et al.
PARKINSONISM & RELATED DISORDERS (2015)
CSF tau and tau/Aβ42 predict cognitive decline in Parkinson's disease
Changqin Liu et al.
PARKINSONISM & RELATED DISORDERS (2015)
Alzheimer's disease cerebrospinal fluid biomarkers are not influenced by gravity drip or aspiration extraction methodology
Alan Rembach et al.
ALZHEIMERS RESEARCH & THERAPY (2015)
CSF biomarkers and clinical progression of Parkinson disease
Sara Hall et al.
NEUROLOGY (2015)
Cerebrospinal Fluid α-Synuclein Predicts Cognitive Decline in Parkinson Disease Progression in the DATATOP Cohort
Tessandra Stewart et al.
AMERICAN JOURNAL OF PATHOLOGY (2014)
CSF Aβ42 predicts early-onset dementia in Parkinson disease
Guido Alves et al.
NEUROLOGY (2014)
Longitudinal assessment of tau and amyloid beta in cerebrospinal fluid of Parkinson disease
Jing Zhang et al.
ACTA NEUROPATHOLOGICA (2013)
Longitudinal change in CSF Tau and Aβ biomarkers for up to 48 months in ADNI
Jon B. Toledo et al.
ACTA NEUROPATHOLOGICA (2013)
Cerebrospinal fluid amyloid-β and phenotypic heterogeneity in de novo Parkinson's disease
Guido Alves et al.
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY (2013)
Tracking pathophysiological processes in Alzheimer's disease: an updated hypothetical model of dynamic biomarkers
Clifford R. Jack et al.
LANCET NEUROLOGY (2013)
APOE ε4 Increases Risk for Dementia in Pure Synucleinopathies
Debby Tsuang et al.
JAMA NEUROLOGY (2013)
Neuropathologic substrates of Parkinson disease dementia
David J. Irwin et al.
ANNALS OF NEUROLOGY (2012)
Accuracy of a Panel of 5 Cerebrospinal Fluid Biomarkers in the Differential Diagnosis of Patients With Dementia and/or Parkinsonian Disorders
Sara Hall et al.
ARCHIVES OF NEUROLOGY (2012)
An evaluation of the impact of MAPT, SNCA and APOE on the burden of Alzheimer's and Lewy body pathology
Christian Wider et al.
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY (2012)
Diagnostic criteria for mild cognitive impairment in Parkinson's disease: Movement Disorder Society Task Force guidelines
Irene Litvan et al.
MOVEMENT DISORDERS (2012)
Effect Size Estimates: Current Use, Calculations, and Interpretation
Catherine O. Fritz et al.
JOURNAL OF EXPERIMENTAL PSYCHOLOGY-GENERAL (2012)
Qualification of the analytical and clinical performance of CSF biomarker analyses in ADNI
Leslie M. Shaw et al.
ACTA NEUROPATHOLOGICA (2011)
The Parkinson Progression Marker Initiative (PPMI)
Kenneth Marek et al.
PROGRESS IN NEUROBIOLOGY (2011)
CSF amyloid-β and tau proteins, and cognitive performance, in early and untreated Parkinson's Disease: the Norwegian ParkWest study
Guido Alves et al.
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY (2010)
CSF Aβ42 and tau in Parkinson's Disease with Cognitive Impairment
Thomas J. Montine et al.
MOVEMENT DISORDERS (2010)
CSF amyloid β 1-42 predicts cognitive decline in Parkinson disease
A. Siderowf et al.
NEUROLOGY (2010)
A clinico-pathological study of subtypes in Parkinson's disease
M. Selikhova et al.
BRAIN (2009)
Cerebrospinal fluid tau and ptau181 increase with cortical amyloid deposition in cognitively normal individuals: Implications for future clinical trials of Alzheimer's disease
Anne M. Fagan et al.
EMBO MOLECULAR MEDICINE (2009)
Cerebrospinal Tau, Phospho-Tau, and Beta-Amyloid and Neuropsychological Functions in Parkinson's Disease
Yaroslau Compta et al.
MOVEMENT DISORDERS (2009)
Clinical diagnostic criteria for dementia associated with Parkinson's disease
Murat Emre et al.
MOVEMENT DISORDERS (2007)
Cognitive differences in dementia patients with autopsy-verified AD, Lewy body pathology, or both
ML Kraybill et al.
NEUROLOGY (2005)
分享论文
